Drug Profile
ICX RHY
Alternative Names: ICX-RHY-013; VaveltaLatest Information Update: 19 Jul 2017
Price :
$50
*
At a glance
- Originator Intercytex
- Class Fibroblast cell therapies; Skin disorder therapies
- Mechanism of Action Collagen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Epidermolysis bullosa dystrophica
- Suspended Scars